Article
Design and Synthesis of New GS-6207 Subtypes for Targeting HIV-1 Capsid Protein.
International journal of molecular sciences - 27 Mar 2024
Akther Thamina, McFadden William M, Zhang Huanchun, Kirby Karen A, Sarafianos Stefan G, Wang Zhengqiang
Abstract excerpt
HIV-1 capsid protein (CA) is the molecular target of the recently FDA-approved long acting injectable (LAI) drug lenacapavir (GS-6207). The quick emergence of CA mutations resistant to GS-6207 necessitates the design and synthesis of novel sub-chemotypes. We have conducted the structure-based design of two new sub-chemotypes combining the scaffold of GS-6207 and the N-terminal cap of PF74 analogs, the other...
Topics
- Capsid Proteins
- HIV-1
- Molecular Docking Simulation
- Anti-HIV Agents
- Mutation